Published in Lancet on February 13, 1993
Drug-induced uveitis. J Ophthalmic Inflamm Infect (2013) 1.11
Involvement of interleukin-1 in the inflammatory actions of aminobisphosphonates in mice. Br J Pharmacol (2000) 0.93
Bilateral acute anterior uveitis after alendronate. Br J Ophthalmol (2002) 0.88
Inhibition of inflammatory actions of aminobisphosphonates by dichloromethylene bisphosphonate, a non-aminobisphosphonate. Br J Pharmacol (1999) 0.80
Retrobulbar optic neuritis after pamidronate administration in a patient with a history of cutaneous porphyria. Clin Rheumatol (1997) 0.78
Risedronate-associated scleritis: a case report and review of the literature. Clin Rheumatol (2012) 0.75
Skeletal disease in primary hyperparathyroidism. J Bone Miner Res (1989) 3.00
Fractures attributable to osteoporosis: report from the National Osteoporosis Foundation. J Bone Miner Res (1997) 2.11
Osteoporosis and low bone mass in premenopausal and perimenopausal women. Endocr Pract (2001) 1.81
Cost-effectiveness of Denosumab for the treatment of postmenopausal osteoporosis. Osteoporos Int (2010) 1.69
Nephrolithiasis and bone involvement in primary hyperparathyroidism. Am J Med (1990) 1.39
Effects of dichloromethylene diphosphonate on skeletal mobilization of calcium in multiple myeloma. N Engl J Med (1980) 1.18
2,3-Dimercaptosuccinic acid as an antidote for lead intoxication. Clin Pharmacol Ther (1985) 1.15
Predictors of falls among postmenopausal women: results from the National Osteoporosis Risk Assessment (NORA). Osteoporos Int (2008) 1.15
Effects of childhood leukemia and chemotherapy on puberty and reproductive function in girls. N Engl J Med (1976) 1.08
A randomized, double-blind comparison of risedronate and etidronate in the treatment of Paget's disease of bone. Paget's Risedronate/Etidronate Study Group. Am J Med (1999) 1.08
Burden of non-hip, non-vertebral fractures on quality of life in postmenopausal women: the Global Longitudinal study of Osteoporosis in Women (GLOW). Osteoporos Int (2012) 1.07
Calcium and vitamin D intake influence bone mass, but not short-term fracture risk, in Caucasian postmenopausal women from the National Osteoporosis Risk Assessment (NORA) study. Osteoporos Int (2007) 1.06
Wrist fracture as a predictor of future fractures in younger versus older postmenopausal women: results from the National Osteoporosis Risk Assessment (NORA). Osteoporos Int (2007) 1.05
Beyond bone mineral density: can existing clinical risk assessment instruments identify women at increased risk of osteoporosis? J Intern Med (2004) 1.05
A clinical approach to diagnosis and management of Paget's disease of bone. J Bone Miner Res (2001) 1.04
Disease-specific perception of fracture risk and incident fracture rates: GLOW cohort study. Osteoporos Int (2013) 1.00
An approach for identifying postmenopausal women age 50-64 years at increased short-term risk for osteoporotic fracture. Osteoporos Int (2007) 0.96
Long-term therapy of Paget's disease of bone with EHDP. Arthritis Rheum (1980) 0.92
Osteoporosis care at risk in the United States. Osteoporos Int (2008) 0.91
Gait analysis of patients who have Paget disease. J Bone Joint Surg Am (1989) 0.91
Non-hip, non-spine fractures drive healthcare utilization following a fracture: the Global Longitudinal Study of Osteoporosis in Women (GLOW). Osteoporos Int (2012) 0.88
The challenges of peripheral bone density testing: which patients need additional central density skeletal measurements? J Clin Densitom (1998) 0.88
Hypercalcemia of malignancy: treatment with intravenous dichloromethylene diphosphonate. Ann Intern Med (1981) 0.87
Seeking the elusive etiology of Paget disease: a progress report. J Bone Miner Res (1996) 0.85
Antiresorptive effect of a single infusion of microgram quantities of zoledronate in Paget's disease of bone. Calcif Tissue Int (1997) 0.85
The influence of severe illness on gonadotropin secretion in the postmenopausal female. J Clin Endocrinol Metab (1977) 0.85
Impact of clinical fractures on health-related quality of life is dependent on time of assessment since fracture: results from the FREEDOM trial. Osteoporos Int (2011) 0.85
Clinical and biochemical effects of EHDP in Paget's disease of bone: patterns of response to initial treatment and to long-term therapy. Metab Bone Dis Relat Res (1981) 0.83
Paget's disease of bone. Bull N Y Acad Med (1980) 0.83
Osteoporosis practice patterns in 2006 among primary care physicians participating in the NORA study. Osteoporos Int (2007) 0.82
A human myeloma immunoglobulin G binding four moles of calcium associated with asymptomatic hypercalcemia. J Clin Immunol (1984) 0.82
New evidence for intrinsic follicle-stimulating hormone-like activity in human chorionic gonadotropin and luteinizing hormone. Endocrinology (1978) 0.82
Regional and age-related variations in the proportions of hip fractures and major fractures among postmenopausal women: the Global Longitudinal Study of Osteoporosis in Women. Osteoporos Int (2011) 0.82
Maintenance etidronate in the prevention of malignancy-associated hypercalcemia. Arch Intern Med (1987) 0.82
Comment on: Cost-effectiveness of denosumab for the treatment of postmenopausal osteoporosis. Osteoporos Int (2011) 0.79
Effects of dopamine blockade on gonadotropins and testosterone in men. Am J Psychiatry (1980) 0.78
Effects of dichloromethylene diphosphonate in women with breast carcinoma metastatic to the skeleton. Am J Med (1983) 0.78
Tumor-induced osteomalacia. Kinetics of calcium, phosphorus, and vitamin D metabolism and characteristics of bone histomorphometry. Am J Med (1987) 0.77
Therapy of hypercalcemia due to parathyroid carcinoma with intravenous dichloromethylene diphosphonate. Am J Med (1982) 0.76
Management of Paget's disease of bone in the era of new and more potent bisphosphonates. Endocr Pract (2004) 0.75
A potent new bisphosphonate for Paget's disease of bone. Am J Med (1996) 0.75
"Crocodile tears" and Paget's disease: case report. Neurosurgery (1980) 0.75
Breast cancer and osteolytic metastases: can bisphosphonates help? Nat Med (1997) 0.75
Risedronate in Paget's disease: preliminary results of a multicenter study. Semin Arthritis Rheum (1994) 0.75
Dichloromethylene diphosphonate action in hematologic and other malignancies. Bone (1987) 0.75
Chronic lymphocytic leukemia and hypercalcemia: treatment with dichloromethylene diphosphonate. Metab Bone Dis Relat Res (1984) 0.75
Diagnosis and treatment of Paget's disease of bone. Compr Ther (1983) 0.75